afternoon business Good XX, to financial the for Thank call and for and update Bioscience. March the results Daré you. welcome quarter XXXX ended
discuss review Our is some important anticipated on our development milestones highlight since and XXXX. first March plan and our to quarter in today objectives call recent results,
are to provisions Before we forward-looking remind laws within Any considered the statements meaning and uncertainties. the made known not to or from during statements are statements of Actual by statements. Litigation or federal which today’s historical Reform securities harbor that this events be XXXX. begin, to you call these I’d should anticipated the unknown made differ due Securities Private pursuant materially that those of and facts risks of like results include could discussion of safe forward-looking the Act will implied statements
on place not statements. forward-looking should undue You reliance
filings, the XX, Form was qualified ended the March today. SEC XXXX by are in for year XX-Q company’s entirety statements filed Forward-looking their the statements including which cautionary in our
point to that statements reflect I’d May to call, this as by new XXXX. or required today, law. call no is current out information forward-looking like the only of this content XX, undertakes developments after Daré includes update also any time-sensitive obligation of that information to except as
market principles. which the candidate portfolio, solely ingredients are the deliver and while product product potential of in And address women’s clear product focused concept uses first each form Each Each core FDA-approved characterized care. Daré’s and ideally, on and/or a time, XX pharmaceutical a must candidates, one development reminder, in meaningful or to improvement nearing can candidate or risk. because both, persistent must built in to which health of cost, includes Phase three mitigate and need. squarely product proof upon a which has stage a of development, first be we diversified the over X of following opportunity As active the and is is even seek development candidate standard unmet category or line have demonstrated clinical
efforts for innovation menopause, focused XXXX. our for female are of Phase Sildenafil sexual Phase activities and top On menopause hormone-free plans milestones and atrophy study discussed license candidate expect year vaginal XXXX intravaginally to the for plans a study fertility. with hormone administered as disorder, XX related results line for the is ring study health recent initiation will activities support our as update health, X Bayer, health, sexual for the the by anticipated results XACIATO our for for single vaginal DARE-VVAX, DARE-HRTX The monthly, and for reproductive financial hormone-free clinical investigational call, potential current X IND-related RESPOND Ovaprene DARE-HRTX, contraceptive clinical under study Our category, contraception, vulvar study for Phase are our X Phase agreement commercial well are we which Ovaprene’s vasomotor intravaginal be and in DARE-VVAX. day and our investigational key Xb Cream pivotal launch for therapy whose U.S. U.S. first-in the Organon. arousal IND-related which the treatment application. pre-market rights we of symptoms intravaginal clinical investigational of of the investigational
will quarter, year. call, for otherwise anticipated On XXXX. our will of vaginal to menstrual diclofenac today’s of additionally, on or primary but which data this conduct, our results first this top focus and our dysmenorrhea, quarter X the Phase is hydrogel quarter And Lisa the this milestones line formulation treat DARE-PDMX, shortly, review investigational XXXX cramps, study second financial we
and Phase of the X.X%, So by on line results, XACIATO the the today in Xb study time commercial we’ll spend Cream launch Sildenafil our Organon. top namely, U.S. RESPOND
We’ll start we’ll market to will as Xb the about Xb objectives context both review RESPOND with in highlight anticipated disorder, unserved exploratory for Phase dynamics will arousal so talk to the update excited this erectile study And we data provide conducting that’s this to female importantly, readout. the and upcoming Cream Sildenafil for be we’re which top study for indication analogous why sexual Phase men. line yet dysfunction the
over the looking FSAD. Organon the update With XACIATO hallmark then and will call I’ll John, sensations an we’re the on arousal Sildenafil of response sexual female Cream and physical lack of the launch or disorder distress that genital to who turn are activities. provide address to arousal X.X%, associated
analogous I well FSAD as addressable of as the ED terms upfront, also quite in and pharmacology the comparable of are in both men, As markets in pathophysiology is the target size. condition or mentioned to dysfunction erectile the
As we Phase a line you expect. to give what data sense can readout we the wanted this approach Xb top expected quarter, you of
of and vaginal formulation both licensor, our the which blood First, this active blood increased demonstrated when by sensing the tissue, to as refresher, Viagra, provide of Daré concept proof data genital via previously is cream female and assessed by same that SST, conducted activity way in sildenafil, flow its the target ingredient the is of studies achieving that internal assessed the tissue, flow. These an probe when camera. to be in formulation increasing temperature an external
practical reported as a designed referred sensors vaginal potential exploratory questions genital to ask ways the evaluate sensations number X setting. endpoints women Obviously, their different in genital the are to Cream at-home and not evaluate Thus, Sildenafil probes to improvements, of Phase a their patient outcomes performance program. study for about to temperature of which Xb Phase and was and
appropriate way So Phase the forward identify program. reported the we outcomes into X patient and select to could this take
Phase read the we’re that’s So expecting Xb what in out.
of be respond could as market We’ve about as our Cream, numerous X.X% wait the So why the terms opportunity. We’ve we our with mentioned the everyone patients FSAD also genital we’re in so or that is designed a on of symptoms associated that large lack candidate development it’s to specifically the Sildenafil only remind the arousal excited great it’s that Xb knowledge our Phase as for program the larger to potential data to also that stage mentioned calls product readout, belief time ED market. FSAD FSAD. address is
As needed to to genital the associated facilitate innovative sildenafil prior I activity sexual where the response arousal and genital vasodilation blood directly arousal those directly formulation women tissue commonly our be topical improve mentioned, cream to physical increase demand the and Viagra active to of is sildenafil in deliver to ingredient lack on the address for the is designed to sensations used flow and FSAD. with to
to the entirely product FDA-approved FSAD treat comparable as be first market addressable of So size and an to create Sildenafil potential ED. Cream has new the market
back most to in it that the product time, ever of the To to quarter than period any there were According in and first the X.X market. was helping full its Viagra double on million for product market. prescribed to we launch product the for to in on that pharmaceutical making into XXXX. need launches According quarter to the only context, put of in most article filled one some successful same the of during the look that market prescriptions of more in cap. XXX,XXX Pfizer’s an history prescriptions physicians published at its Viagra market time, the that CNNMoney, dynamics at time first And source,
the drug our we be patient of It order program. developer improvements blazing can the and different appropriate I to a identify to first with and ask women in as reported their are questions select path ways take number Phase to where need into X Xb a about potential to forward a genital as be mentioned, sensations outcomes new to as exploratory we evaluate challenging study Phase
But uptake where we that intervention similarities and see both lack viable between which a and is Viagra, number that markets. often and a principally described launch a I impressive. patients in from And level incredibly to created a situation significant led depression, frustration. men of the pharmaceutical ED had of before FSAD condition, providers isolation ED To Viagra in of
women or FSAD, provider were or ask now ED have viable without help is their men to intervention for with with a the As reluctant conversation like for Viagra, case information. a
men feeling they often to partners personal friends felt it men a the when about and conducted their XXXX noted their symptom Journal, and well men available as provided their authors became British Viagra to once silence condition. to their feeling study talk generally or that that suffered happy The in great many reported in them wellbeing. affected relationships, unable the also that elated reported relief, authors as as According left noted improvements embarrassed by Medical ED elating, and
frustration due have dissatisfaction and sex know FSAD. These about their to are problems. often their their sexual condition mirror women uncovered insights feeling about the and similarly that that unhappiness lives, general findings with reluctant with their partners we speak report to We
to shame or women We alone an and of in suffer FDA silence affected also often are approved believe are without feeling that by intervention, a left embarrassment.
we the to plan to similarities we first a of potential reporting top-line for step Xb Therefore, conclusion, our and for Subsequent full a emotional that Sildenafil enormous unmet top the the of proposals results, Phase number as study, to quarter condition need patient set pathophysiology program. the the tools impact data in we’ve and demand of of the Given from report the line large ED as Cream. our there product when study exploratory we this study to been points the assessment see pent-up terms as bring the to in is amount Phase the that the we for and end data we X the we psychological well utilized the a and population FDA formalize have the in to like we’re believe the of to excited discussing, FSAD the regarding will evaluate study.
clinical Xb recently This clinical Phase These expected part X initiation the announced this to Phase Phase enroll support and data Sildenafil X in around data women the the for setting. in to we the and respond important now clinical product in to XX our study is clinical Cream a compliment are a expected a addition add where to from and of program. data trial findings forthcoming non-clinical existing preparation an home, comprehensive thermography study development the regulatory used supplemental Xb year. to Sildenafil development plan be package completed a and for Cream our program. are ongoing In clinical of study at our These of thermography to study Phase was
Our goal distressed for solution treatment United alone condition. address are needed in to their no and bring to or no women estimated sexual to is and option States be with XX to low million the FDA-approved much who the seek a arousal
was goal Our be women as FDA-approved Sildenafil first Viagra for for FSAD men the with is ED. to product for Cream with
to collaborator, our the for detailed NIH not pivotal note with to programs be on planning Ovaprene expect providing NICHD start clinical but continue and mid-XXXX study later that expect on what the today, other updates enrollment the the submission of in we enjoying on pivotal patient we’ve this contraceptive year the registration. study single Now, required planned support and been to want do development to I we’re to commence working PMA for we
mention also that DARE-PDMX thrilled that with I interest underway Australia. want to we is our the study in in are
by of investigational data global expected size that diclofenac The $XX this to this this XXXX. are billion a is As treatment was is to billion treat that the is suggests research same to top-line drug in formulation hydrogel expected vaginally, product market recent anti-inflammatory estimated XACIATO. at dysmenorrhea the increase for delivering our valued in formulation dysmenorrhea, market XXXX, year technology that reminder, that and primary cramps be our proprietary using or by to non-steroidal and used $XX menstrual the market
to on John I development a those programs, XACIATO activities. updates it commercial the to the launch over will now with update So provide on turn
